X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (577) 577
male (480) 480
dioxoles - pharmacology (434) 434
humans (377) 377
index medicus (365) 365
dioxoles - administration & dosage (306) 306
female (302) 302
rats (284) 284
mice (240) 240
dioxoles - therapeutic use (191) 191
pharmacology & pharmacy (169) 169
oncology (164) 164
trabectedin (139) 139
middle aged (127) 127
adult (125) 125
tetrahydroisoquinolines - administration & dosage (125) 125
dioxoles - adverse effects (112) 112
dose-response relationship, drug (96) 96
chemotherapy (94) 94
aged (92) 92
rats, sprague-dawley (92) 92
tetrahydroisoquinolines - adverse effects (84) 84
cancer (81) 81
tetrahydroisoquinolines - therapeutic use (80) 80
sarcoma - drug therapy (76) 76
dioxoles - pharmacokinetics (75) 75
lignans - pharmacology (74) 74
antineoplastic agents, alkylating - therapeutic use (73) 73
disease models, animal (71) 71
treatment outcome (71) 71
rats, wistar (70) 70
time factors (70) 70
antineoplastic combined chemotherapy protocols - therapeutic use (68) 68
sarcoma (66) 66
et-743 (62) 62
antineoplastic agents, alkylating - adverse effects (61) 61
liver - metabolism (61) 61
administration, oral (60) 60
mice, inbred c57bl (59) 59
antineoplastic agents, alkylating - administration & dosage (57) 57
research (57) 57
biochemistry & molecular biology (54) 54
expression (54) 54
doxorubicin - administration & dosage (53) 53
inhibition (53) 53
lignans - administration & dosage (53) 53
ovarian neoplasms - drug therapy (53) 53
lignans (52) 52
liver - drug effects (52) 52
ecteinascidin-743 (51) 51
sesamin (51) 51
dioxoles - chemistry (49) 49
dioxoles - metabolism (49) 49
drug administration schedule (48) 48
disease-free survival (47) 47
gene expression (44) 44
analysis (43) 43
oxidative stress (43) 43
soft-tissue sarcoma (43) 43
adrenergic beta-agonists - pharmacology (42) 42
benzamides - pharmacology (42) 42
care and treatment (41) 41
research article (41) 41
antitumor-activity (40) 40
article (40) 40
liver (40) 40
tetrahydroisoquinolines (40) 40
infusions, intravenous (39) 39
nutrition & dietetics (38) 38
piperidines - pharmacology (38) 38
neurosciences (37) 37
sarcoma - pathology (37) 37
in vitro techniques (36) 36
phase-ii (36) 36
rodents (36) 36
cells, cultured (35) 35
in-vitro (35) 35
medicine (35) 35
signal transduction (34) 34
young adult (34) 34
aged, 80 and over (33) 33
cell biology (33) 33
drug synergism (33) 33
metabolism (33) 33
ovarian cancer (33) 33
apoptosis (32) 32
cells (32) 32
pharmacokinetics (32) 32
rats, inbred strains (32) 32
activation (31) 31
blood pressure - drug effects (31) 31
doxorubicin - analogs & derivatives (31) 31
medicine & public health (31) 31
pegylated liposomal doxorubicin (31) 31
rat (31) 31
signal transduction - drug effects (31) 31
cell line, tumor (30) 30
drug interactions (30) 30
multidisciplinary sciences (30) 30
neoplasms - drug therapy (30) 30
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (802) 802
Japanese (17) 17
French (8) 8
Chinese (7) 7
Russian (3) 3
German (2) 2
Korean (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 812 - 822
Summary Background Previous trials from our group suggested an overall survival benefit with five cycles of adjuvant full-dose epirubicin plus ifosfamide in... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CRITERIA | THERAPY | RECIST | CLINICAL-TRIAL | HIGH-GRADE | ONCOLOGY | DOSE ADJUVANT CHEMOTHERAPY | EXTREMITIES | TUMOR RESPONSE ASSESSMENT | IFOSFAMIDE | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Trabectedin | Sarcoma - therapy | Young Adult | Neurilemmoma - therapy | Dioxoles - administration & dosage | Back | Adult | Neutropenia - chemically induced | Child | Extremities | Soft Tissue Neoplasms - therapy | Dacarbazine - administration & dosage | Thoracic Wall | Sarcoma, Synovial - therapy | Deoxycytidine - administration & dosage | Risk Factors | Docetaxel | Anemia - chemically induced | Etoposide - administration & dosage | Tetrahydroisoquinolines - administration & dosage | Thrombocytopenia - chemically induced | Abdominal Wall | Sarcoma - pathology | Leiomyosarcoma - therapy | Disease-Free Survival | Taxoids - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Neoadjuvant Therapy - methods | Adolescent | Soft Tissue Neoplasms - pathology | Aged | Deoxycytidine - analogs & derivatives | Liposarcoma, Myxoid - therapy | Care and treatment | Anthracyclines | Sarcoma | Adjuvant treatment | Clinical trials | Product development | Standards | Cancer
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2017, Volume 35, Issue 29, pp. 3347 - 3353
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2017, Volume 145, Issue 1, pp. 208 - 216
Abstract Leiomyosarcoma, a rare tumor subtype, accounts for 1% of all uterine malignancies, but contributes to a significant proportion of uterine cancer... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Targeted therapies | Uterine sarcoma | Rare tumor | Uterine morcellation | Leiomyosarcoma | ADJUVANT CHEMOTHERAPY | MUSCLE TUMOR | SUPRACERVICAL HYSTERECTOMY | GEMCITABINE PLUS DOCETAXEL | PROGNOSTIC-FACTORS | EUROPEAN ORGANIZATION | RANDOMIZED CLINICAL-TRIAL | PHASE-II | STAGE-I | OBSTETRICS & GYNECOLOGY | ONCOLOGY | SOFT-TISSUE SARCOMA | Uterine Neoplasms - therapy | Uterine Neoplasms - pathology | Humans | Uterine Neoplasms - epidemiology | Leiomyoma - diagnosis | Leiomyosarcoma - epidemiology | Angiogenesis Inhibitors - administration & dosage | Diagnostic Errors | Dioxoles - administration & dosage | Leiomyoma - surgery | Female | Chemotherapy, Adjuvant | Uterine Neoplasms - diagnosis | Aromatase Inhibitors - therapeutic use | Doxorubicin - administration & dosage | Leiomyosarcoma - pathology | Pyrimidines - administration & dosage | Deoxycytidine - administration & dosage | Hysterectomy - methods | Laparoscopy | Tetrahydroisoquinolines - administration & dosage | Uterine Myomectomy | Leiomyosarcoma - therapy | Morcellation | Taxoids - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leiomyosarcoma - diagnosis | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Medical colleges | Anthracyclines | Chemotherapy | Analysis | Immunotherapy | Angiogenesis inhibitors | Drug approval | Epidemiology | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2010, Volume 28, Issue 19, pp. 3107 - 3114
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 312 - 319
Journal Article
Annals of Oncology, ISSN 0923-7534, 2011, Volume 22, Issue 1, pp. 39 - 48
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2005, Volume 23, Issue 9, pp. 1867 - 1874
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 01/2017, Volume 27, Issue 2, pp. 176 - 179
(−)-Cubebin (CUB), isolated from seeds of , was used as starting material to obtain the derivatives (−)-hinokinin (HK) and (−)-O-benzyl cubebin (OBZ). Using... 
Anti-inflammatory activity | (−)-Hinokinin | Piper cubeba | (−)-Cubebin | (−)-O-benzylcubebin | CHEMISTRY, MEDICINAL | APPROXIMATION | (-)-Cubebin | LEAVES | CHEMISTRY, ORGANIC | (-)-Hinokinin | SWISS-MODEL | DENSITY | ZANTHOXYLUM-NARANJILLO | (-)-0-benzylcubebin | LIGNANS | ELECTROSTATICS | Rats, Wistar | Furans - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Male | Benzodioxoles - administration & dosage | Cyclooxygenase 2 Inhibitors - chemistry | Dioxoles - chemical synthesis | Lignans - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Cyproheptadine - pharmacology | Polysorbates - pharmacology | Dextrans - pharmacology | Dioxoles - administration & dosage | Furans - chemistry | Computer Simulation | Dioxoles - pharmacology | 4-Butyrolactone - chemistry | Benzodioxoles - chemistry | Lignans - chemical synthesis | Rutaceae - chemistry | Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis | Benzodioxoles - chemical synthesis | Cyclooxygenase 2 Inhibitors - chemical synthesis | Dinoprostone - pharmacology | Catalytic Domain | Cyclooxygenase 2 Inhibitors - pharmacology | Lignans - chemistry | Cyclooxygenase 2 - chemistry | Cyclooxygenase 2 Inhibitors - administration & dosage | 4-Butyrolactone - pharmacology | 4-Butyrolactone - chemical synthesis | Dioxoles - chemistry | Indomethacin - pharmacology | Lignans - isolation & purification | Lignans - administration & dosage | Animals | 4-Butyrolactone - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Ligands | Mice | Molecular Docking Simulation | 4-Butyrolactone - analogs & derivatives | Edema - chemically induced | Furans - chemical synthesis | Benzodioxoles - pharmacology | Furans - administration & dosage
Journal Article
International Journal of Gynecological Cancer, ISSN 1048-891X, 11/2017, Volume 27, Issue 9, pp. 1872 - 1876
INTRODUCTIONIn ovarian cancer, it is uncertain which chemotherapy regimen is more clinically effective and cost-effective for the treatment of recurrence;... 
Costs of drugs | Randomized phase 3 trials | Recurrent advanced ovarian cancer | ESMO-MCBS | Second-line therapy | CLINICAL BENEFIT SCALE | SURVIVAL | PEGYLATED LIPOSOMAL DOXORUBICIN | PERSPECTIVE | CARE | OBSTETRICS & GYNECOLOGY | MAGNITUDE | ONCOLOGY | THERAPIES | ECONOMICS | Drug Costs | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neoplasm Recurrence, Local - economics | Humans | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - administration & dosage | Dioxoles - economics | Polyethylene Glycols - economics | Trabectedin | Neoplasms, Glandular and Epithelial - economics | Dioxoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - economics | Doxorubicin - analogs & derivatives | Female | Randomized Controlled Trials as Topic - economics | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Doxorubicin - administration & dosage | Paclitaxel - economics | Deoxycytidine - administration & dosage | Tetrahydroisoquinolines - economics | Carboplatin - administration & dosage | Doxorubicin - economics | Survival Rate | Tetrahydroisoquinolines - administration & dosage | Deoxycytidine - economics | Carboplatin - economics | Antineoplastic Agents - economics | Polyethylene Glycols - administration & dosage | Disease-Free Survival | Clinical Trials, Phase III as Topic - economics | Ovarian Neoplasms - economics | European Union | Cost-Benefit Analysis | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Deoxycytidine - analogs & derivatives
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 76, pp. 84 - 92
Abstract Background Preclinical models that mimic pathological and molecular features of solitary fibrous tumour (SFT) represent an important tool to select... 
Hematology, Oncology and Palliative Medicine | Eribulin | Xenograft | Sarcoma | Ifosfamide | Mice model | Solitary fibrous tumour | Metastasis | Trabectedin | Doxorubicin | Dacarbazine | Chemotherapy | Treatment | Anthracycline | MECHANISM | PHASE-2 | IDENTIFICATION | TEMOZOLOMIDE | MESYLATE | ONCOLOGY | RECURRENT | HEMANGIOPERICYTOMA | EXPRESSION | SOFT-TISSUE SARCOMA | Humans | Middle Aged | Soft Tissue Neoplasms - drug therapy | Male | Response Evaluation Criteria in Solid Tumors | Pleural Neoplasms - drug therapy | Retroperitoneal Neoplasms - mortality | Meningeal Neoplasms - drug therapy | Retroperitoneal Neoplasms - drug therapy | Dioxoles - administration & dosage | Adult | Female | Retrospective Studies | Doxorubicin - administration & dosage | Cerebellar Neoplasms - drug therapy | Dacarbazine - administration & dosage | Soft Tissue Neoplasms - mortality | Solitary Fibrous Tumors - drug therapy | Solitary Fibrous Tumors - mortality | Cerebellar Neoplasms - mortality | Ketones - administration & dosage | Survival Rate | Tetrahydroisoquinolines - administration & dosage | Pleural Neoplasms - mortality | Kidney Neoplasms - mortality | Mice, SCID | Blotting, Western | Meningeal Neoplasms - mortality | Xenograft Model Antitumor Assays | Disease-Free Survival | Animals | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Kidney Neoplasms - drug therapy | Furans - administration & dosage | Analysis | Melanoma | Stem cells | Anthracyclines | Cancer
Journal Article
Health Technology Assessment, ISSN 1366-5278, 01/2015, Volume 19, Issue 7, pp. 1 - 524
Background: Ovarian cancer is the fifth most common cancer in the UK, and the fourth most common cause of cancer death. Of those people successfully treated... 
COST-EFFECTIVENESS ANALYSIS | CLINICAL-PRACTICE GUIDELINES | RANDOMIZED PHASE-II | LONG-TERM SURVIVAL | HEALTH CARE SCIENCES & SERVICES | PLATINUM-BASED CHEMOTHERAPY | SINGLE-AGENT PACLITAXEL | QUALITY-OF-LIFE | PLUS CARBOPLATIN | 1ST-LINE THERAPY | EPITHELIAL OVARIAN | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dioxoles - adverse effects | Humans | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Ovarian Neoplasms - mortality | Polyethylene Glycols - economics | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - pathology | Topotecan - economics | Dioxoles - administration & dosage | Neoplasm Invasiveness - pathology | Antineoplastic Combined Chemotherapy Protocols - economics | Doxorubicin - analogs & derivatives | Female | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Doxorubicin - administration & dosage | Quality-Adjusted Life Years | Paclitaxel - economics | Double-Blind Method | Risk Assessment | Deoxycytidine - administration & dosage | Doxorubicin - economics | Treatment Outcome | United Kingdom | Tetrahydroisoquinolines - administration & dosage | Tetrahydroisoquinolines - adverse effects | Deoxycytidine - economics | Polyethylene Glycols - administration & dosage | Randomized Controlled Trials as Topic | Disease-Free Survival | Health Care Costs | Ovarian Neoplasms - economics | Cost-Benefit Analysis | Survival Analysis | Topotecan - administration & dosage | Neoplasm Staging | Deoxycytidine - analogs & derivatives
Journal Article